Back to Search
Start Over
Clin Infect Dis
- Source :
- Clinical Infectious Diseases, Clinical Infectious Diseases, Oxford University Press (OUP), In press, 70 (5), pp.943-946. ⟨10.1093/cid/ciz577⟩
- Publication Year :
- 2020
- Publisher :
- HAL CCSD, 2020.
-
Abstract
- We evaluated an elvitegravir–cobicistat–emtricitabine–tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis. The completion rate and adherence were good, and the tolerance was acceptable; no seroconversion was observed. We confirm that this regimen could be appropriate for postexposure prophylaxis.
- Subjects :
- 0301 basic medicine
Microbiology (medical)
medicine.medical_specialty
Anti-HIV Agents
medicine.medical_treatment
030106 microbiology
Human immunodeficiency virus (HIV)
HIV Infections
Quinolones
medicine.disease_cause
03 medical and health sciences
0302 clinical medicine
Internal medicine
Emtricitabine
Humans
Medicine
MORPH3Eus
030212 general & internal medicine
Seroconversion
Post-exposure prophylaxis
Tenofovir
Adverse effect
Alanine
Elvitegravir/cobicistat/emtricitabine/tenofovir
business.industry
Adenine
Single tablet regimen
3. Good health
Clinical trial
Drug Combinations
Regimen
Infectious Diseases
HIV-1
Cobicistat
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
business
Tablets
Subjects
Details
- Language :
- English
- ISSN :
- 10584838 and 15376591
- Database :
- OpenAIRE
- Journal :
- Clinical Infectious Diseases, Clinical Infectious Diseases, Oxford University Press (OUP), In press, 70 (5), pp.943-946. ⟨10.1093/cid/ciz577⟩
- Accession number :
- edsair.doi.dedup.....2d5204ca01b567c5d0cd87cbd66fb2b2
- Full Text :
- https://doi.org/10.1093/cid/ciz577⟩